A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience · Transitional Cell Carcinoma of Bladder · Urethra Cancer
Phase 1 / Phase 2
Completed
68
2024-06
Industry sponsor intelligence
Altor BioScienceClinical Pipeline.
Lead-sponsor view of Altor BioScience's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 6
- Recruiting
- 0
- Active
- 0
- Completed
- 3
- Results posted
- 4
- Avg enrollment
- 23
Pipeline overview
Programs by phase and activity.
Velocity
Altor BioScience trials by start year
Study start year · indexed snapshot
Development
Trials by phase
10phase labels
Early Phase 10
Phase 16
Phase 24
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Pemvidutide → | 6 | 6 | 4 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Altor BioScience · Metastatic Melanoma
Phase 1 / Phase 2
Completed
25
2016-10
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience · Progressive Metastatic Malignancies
Phase 1
Completed
26
2013-07
Search sponsor records
All Altor BioScience studies.
This page groups studies where Altor BioScience is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
6 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT01625260A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerJul 19, 2024NCT01326871A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerJun 25, 2024NCT01670994QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaJun 18, 2024NCT01029873QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaOct 27, 2016NCT01478074ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaJan 3, 2014NCT00496860Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesJul 22, 2013